Streetbeat News

DSNKY

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.co.jp/

CEO

Sunao Manabe

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

第一三共（株） is a chemicals company based out of 日本橋本町３丁目５－１第一三共本社ビルａ館ｂ館, 中央区, 東京都, japan.

Open

28.85

Mkt cap

55B

Volume

9.7K

High

28.96

P/E Ratio

34.24

52-wk high

42.48

Low

28.67

Div yield

0.01

52-wk low

25.11

Daiichi Sankyo Co has raised its FY2024 GAAP EPS guidance from $0.44 to $0.80 and its sales outlook from $10.55 billion to $12.29 billion.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:16 am

Daiichi Sankyo Co reported a significant increase in its Q2 earnings per share (EPS) and sales compared to the same period last year. The EPS rose by 57.14% to $0.22, while sales increased by 15.43% to $3.00 billion.

Portfolio Pulse from totan@benzinga.com

October 31, 2024 | 9:52 am

AstraZeneca's Phase 3 trial of datopotamab deruxtecan (Dato-DXd) for breast cancer did not achieve statistical significance in overall survival, though it showed improvement in progression-free survival and patient-reported outcomes. The safety profile was consistent with previous analyses. AstraZeneca's stock is down 1.86% in premarket trading.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 11:44 am

Merck & Co Inc (MRK) and Daiichi Sankyo's lung cancer drug, patritumab deruxtecan, met its primary endpoint in a phase 3 trial, showing significant improvement in progression-free survival for EGFR-mutated NSCLC patients. The safety profile was consistent with previous trials. Meanwhile, Summit Therapeutics' ivonescimab showed better results than Merck's Keytruda in a separate trial.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 11:58 am

AstraZeneca's investigational cancer drug, datopotamab deruxtecan, showed disappointing results in a late-stage lung cancer trial, failing to achieve statistical significance in improving overall survival compared to standard chemotherapy. Despite a numerical improvement in survival, the results did not meet expectations, leading to a decline in AstraZeneca's stock price.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 12:16 pm

Daiichi Sankyo and Merck's drug, ifinatamab deruxtecan, shows a 54.8% response rate in a Phase 2 trial for small cell lung cancer, with 12 mg/kg chosen as the optimal dose for further studies.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:13 am

Daiichi Sankyo and AstraZeneca's ENHERTU has received its eighth Breakthrough Therapy Designation from the FDA for treating specific patients with HER2 low or ultralow metastatic breast cancer. This designation is based on the results of the DESTINY-Breast06 phase 3 trial.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 6:29 am

Macquarie has identified 10 Asian stocks, including TSMC and SK Hynix, as top buying opportunities amidst global market volatility. These stocks are seen as resilient to recession fears and are expected to rebound strongly.

Portfolio Pulse from Surbhi Jain

August 07, 2024 | 1:16 pm

Daiichi Sankyo and Merck have expanded their partnership to co-develop and co-commercialize MK-6070, a DLL3 targeting T-cell engager, for cancer treatment. Merck retains exclusive rights in Japan.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:50 am

Merck & Co Inc (NYSE:MRK) reported strong Q2 earnings with revenue and EPS beating estimates, driven by robust Keytruda sales. However, acquisition costs have led to a downward revision in the annual profit forecast. The company also received an FDA Complete Response Letter for a lung cancer drug application with partner Daiichi Sankyo.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 12:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.